[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100480767":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":19,"responsibleParty":38,"collaborators":11,"id":41,"slug":11,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":11,"eligibilityCriteria":45,"healthyVolunteers":42,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":11,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":11,"overallStatus":22,"whyStopped":11,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"First Affiliated Hospital of Guangxi Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Edaravone","EXPERIMENTAL",null,[13],"Drug: Edaravone",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","Edaravone injection 30mg three times a day",[9],[20],{"facility":21,"status":22,"city":23,"state":11,"zip":24,"country":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Yi Du","RECRUITING","Nanning","530021","China",{"type":27,"coordinates":28},"Point",[29,30],108.31667,22.81667,{"lat":30,"lon":29},[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"Yi Du, MD","CONTACT","+86 771 5356507","duyinapoleon@gmail.com",{"type":39,"investigatorFullName":21,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Dr.","100480767",false,"NCT05540262","Edaravone in the Treatment of Optic Neuritis","Inclusion Criteria:\n\n1. Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis\n2. Patients with a first episode of optic neuritis in either eye\n3. First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone\n\nExclusion Criteria:\n\n1. Myopia over 6 diopters\n2. Refractive media opacity affecting assessment of retinal layers and\u002For visual acuity","ALL","18 Years","70 Years",{"count":50,"type":51},50,"ESTIMATED","INTERVENTIONAL",[54],"NA","Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.",[57],"Optic Neuritis","2025-02-25",{"date":60,"type":61},"2025-02-27","ACTUAL",{"date":63,"type":61},"2022-01-15",{"date":65,"type":51},"2025-12-31",{"name":5,"class":6},1]